Dated: December 7, 1999.

John Burckhardt,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 99–32150 Filed 12–10–99; 8:45 am]

BILLING CODE 4163–19–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 96F–0293]

Avecia Inc.; Withdrawal of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the withdrawal, without prejudice to a future filing, of a food additive petition (FAP 6B4516) proposing that the food additive regulations be amended to provide for the safe use of 2-methyl-4,5-trimethylene-4-isothiazolin-3-one as a preservative for paper and paperboard coatings used in contact with food.

FOR FURTHER INFORMATION CONTACT: Vir D. Anand, Center for Food Safety and Applied Nutrition (HFS–215), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3081.

SUPPLEMENTARY INFORMATION: In a notice published in the **Federal Register** of August 27, 1996 (61 FR 44067), FDA announced that a food additive petition (FAP 6B4516) had been filed by Zeneca Inc., Foulkstone 1405, 2d, 1800 Concord Pike, Wilmington, DE 19850–5457. The petition proposed to amend the food additive regulations in § 176.170 *Components of paper and paperboard in contact with aqueous and fatty foods* (21 CFR 176.170) to provide for the safe use of 2-methyl-4,5-trimethylene-4-isothiazolin-3-one as a preservative for paper and paperboard coatings used in contact with food. Since publication of the filing notice, Zeneca Inc.'s, specialty chemicals group has been spun-off to form a new company, Avecia Inc., 1405 Foulk Rd., Wilmington, DE 19850–5457. Avecia Inc., has now withdrawn the petition without prejudice to a future filing (21 CFR 171.7).

Dated: November 29, 1999.

Alan M. Rulis,

Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 99–32100 Filed 12–10–99; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Hematology and Pathology Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Hematology and Pathology Devices Panel of the Medical Devices Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on December 15, 1999, 9 a.m. to 4:30 p.m.

Location: Corporate Bldg., conference room 20B, 9200 Corporate Blvd., Rockville, MD.

Contact Person: Michelle Y. Stuart, Center for Devices and Radiological Health (HFZ–440), Food and Drug Administration, 2098 Gaither Rd., Rockville, MD 20850, 301–594–1293, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12515. Please call the Information Line for up-to-date information on this meeting.

Procedure: On December 15, 1999, from 9 a.m. to 10 a.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by December 13, 1999. Those desiring to make formal oral presentations should notify the contact person by December 13, 1999, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation. Time allotted for the presentations may be limited.

Closed Committee Deliberations: On December 15, 1999, from 10 a.m. to 4:30 p.m., the meeting will be closed to the public. The committee will hear and review trade secret and/or confidential commercial information on a product development protocol (5 U.S.C. 552b(c)(4)). This portion of the meeting is closed to permit discussion of this information.

FDA regrets that it was unable to publish this notice 15 days prior to the December 15, 1999, Hematology and Pathology Devices Panel of the Medical Devices Advisory Committee meeting. Because the agency believes there is some urgency to bring this issue to public discussion and qualified members of the Hematology and Pathology Devices Panel of the Medical Devices Advisory Committee were available at this time, the Commissioner concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: December 7, 1999.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 99–32239 Filed 12–8–99; 4:55 pm]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Care Financing Administration

[HCFA–3029–N]

Medicare Program; Meeting of the Medical and Surgical Procedures Panel of the Medicare Coverage Advisory Committee—January 19 and 20, 2000

AGENCY: Health Care Financing Administration (HCFA), HHS.

ACTION: Notice of meeting.

SUMMARY: This notice announces a public meeting of the Medical and Surgical Procedures Panel of the Medicare Coverage Advisory Committee (MCAC). The panel provides advice and recommendations to the agency about clinical coverage issues. The panel will hear and discuss presentations from interested persons regarding behavioral interventions (pelvic muscle rehabilitation) for the management of non-neurogenic urinary incontinence in adults. The meeting will primarily focus on two management options: biofeedback and pelvic floor electrical stimulation. Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. App. 2, section 10(a)(1) and (a)(2)).

DATES:

The Meeting: The meeting will be held on January 19, 2000 from 8:30 a.m. until 5 p.m., E.D.T., and on January 20, 2000, from 8:30 a.m. until 3:00 p.m., E.D.T.

Deadline for Presentations and Comments: You must submit formal presentations and written comments to the For Further Information Contact by December 29, 1999, 5 p.m., E.D.T.

Special Accommodations: Persons attending the meeting who are hearing or visually impaired and have special requirements, or a condition that requires special assistance or accommodations, are asked to notify the Executive Secretary by December 15, 1999.

ADDRESSES: *The Meeting:* The meeting will be held at the Baltimore Marriott Inner Harbor, 110 S. Eutaw Street, Baltimore, MD 21201.

Presentations and Comments: Submit formal presentations and written comments to Constance A. Conrad, Executive Secretary; Office of Clinical Standards and Quality; Health Care Financing Administration; 7500 Security Boulevard; Mail Stop S3–02–01; Baltimore, MD 21244.

Website: You may access up to date information on this meeting at www.hcfa.gov/quality/8b.htm.

FOR FURTHER INFORMATION CONTACT: Constance A. Conrad, Executive Secretary, 410–786–4631.

SUPPLEMENTARY INFORMATION: On August 13, 1999, we published a notice (64 FR 44231) to describe the MCAC, which provides advice and recommendations to us about clinical coverage issues. This notice announces the following public meeting of the MCAC:

Current Panel Members

Alan M. Garber, M.D.; Michael D. Maves, M.D.; Angus M. McBryde, M.D.; H. Logan Holtgrewe, M.D.; Kenneth P. Brin, M.D.; Les J. Zendle, M.D.; Bruce Sigsbee, M.D.; Linda D. Bradley, M.D.; James P. Rathmell, M.D.; Arnold M. Epstein, M.D.; Phyllis E. Greenberger, M.S.W.; Marshall S. Stanton, M.D.

Meeting Topic

The Panel will hear and discuss presentations from interested persons regarding behavioral interventions for the management of non-neurogenic urinary incontinence in adults. The meeting will primarily focus on two management options: biofeedback and pelvic floor electrical stimulation.

Procedure and Agenda

This meeting is open to the public. The panel will hear oral presentations from the public for approximately 2 hours and 30 minutes on the first day of the meeting. The Panel may limit the number and duration of oral presentations to the time available. It you wish to make formal presentations you must notify the For Further Information Contact, and submit the following by the Deadline for Presentations and Comments date listed in the Dates section of this notice: a brief statement of the general nature of the evidence or arguments you wish to present, the names and addresses of proposed participants, and an estimate of the time required to make the presentation. We will request that you declare at the meeting whether or not you have any financial involvement with manufacturers of any items or services being discussed (or with their competitors).

After the public presentation, we will make a presentation to the Panel. After our presentation, the Panel will deliberate openly on the topic. Interested persons may observe the deliberations, but the Panel will not hear further comments during this time except at the request of the chairperson. At the end of the Panel deliberations, the Panel will allow at least a 30-minute open public session for any attendee to address issues specific to the topic. After which, the members will vote and the panel will make its recommendation.

Authority: 5 U.S.C. App. 2, section 10(a)(1) and (a)(2).

(Catalog of Federal Domestic Assistance Program No. 93.774, Medicare—Supplementary Medical Insurance Program)

Dated: December 7, 1999.

Jeffrey L. Kang,

Director, Office of Clinical Standards and Quality, Health Care Financing Administration.

[FR Doc. 99–32165 Filed 12–10–99; 8:45 am]

BILLING CODE 4120–01–U

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of Inspector General

Program Exclusions: November 1999

AGENCY: Office of Inspector General, HHS.

ACTION: Notice of program exclusions.

During the month of November 1999, the HHS Office of Inspector General imposed exclusions in the cases set forth below. When an exclusion is imposed, no program payment is made to anyone for any items or services (other than an emergency item or service not provided in a hospital emergency room) furnished, ordered or prescribed by an excluded party under the Medicare, Medicaid, and all Federal Health Care programs. In addition, no program payment is made to any business or facility, *e.g.,* a hospital, that submits bills for payment for items or services provided by an excluded party. Program beneficiaries remain free to decide for themselves whether they will continue to use the services of an excluded party even though no program payments will be made for items and services provided by that excluded party. The exclusions have national effect and also apply to all Executive Branch procurement and non-procurement programs and activities.

Subject, city, state	Effective date
PROGRAM-RELATED CONVICTIONS	
CAVA, JOSE LA MIRADA, CA	12/20/1999
DE LA ROSA, ALBERTO JESUS MIAMI, FL	12/20/1999
DEMERS, KAREN ANN SEATTLE, WA	12/20/1999
FAULKNER, MICHAEL LENEXA, KS	12/20/1999
FERNANDEZ, LUIZ M MIAMI, FL	12/20/1999
FERNANDEZ, CARMEN VALDES MIAMI, FL	12/20/1999
FRAZIER, TRAVIS E POINT, GA	12/20/1999
GRANDA, AGUSTIN F MIAMI, FL	12/20/1999
GREEN, SUZANNE K PRAIRIE VILLAGE, KS	12/20/1999
JENKINS, THOMAS LOUISIANA, MO	12/20/1999
JENKINS, DAVID LOUISIANA, MO	12/20/1999
KENT, DEBORAH JACKSON, MS	12/20/1999
KRATMAN, ALEXANDER EVERETT, WA	12/20/1999
KWAN, DON SHEK KENT, WA	12/20/1999
LANCASTER, PATSY A KIRKSVILLE, MO	12/20/1999
MARTIN, FRANK JONESBORO, AR	12/20/1999
MCKENNA, WORMAN BERNARD HENDERSON, NV	12/20/1999
MEAN, RONG R LONG BEACH, CA	12/20/1999
MEYER, FRANK WILLIAM WARSAW, MO	12/20/1999
MINO ROMERO, ANITA MAE LAKEWOOD, CO	12/20/1999
OLIVER, CHARLES E ANN ARBOR, MI	12/20/1999
ORTIZ, JORGE TOA BAJA, PR	12/20/1999
PERALTA, MARIA TERESA HIALEAH, FL	12/20/1999
POLIAKOV, VITALY REDMOND, WA	12/20/1999
PROBST, JOSEPH C MANCHESTER, KY	12/20/1999
RASIN, PAVEL BELEVUE, WA	12/20/1999
RIVERA-CRUZ, CARLOS	12/20/1999